{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:31:47Z","timestamp":1787016707950,"version":"build-2736575974"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Meningococcal outer membrane vesicle (OMV) vaccines, which are treated with detergents to decrease endotoxin activity, are safe and effective in humans. However, the vaccines elicit serum bactericidal antibody responses largely directed against PorA, which is antigenically variable. We previously prepared a native (non-detergent-treated) OMV vaccine from a mutant of group B strain H44\/76 in which the\n                    <jats:italic>lpxL1<\/jats:italic>\n                    gene was inactivated, which resulted in penta-acylated lipid A with attenuated endotoxin activity. To enhance protection, we overexpressed factor H binding protein (fHbp) from the antigenic variant 1 group. The vaccine elicited broad serum bactericidal antibody responses in mice against strains with fHbp variant 1 (\u223c70% of group B isolates) but not against strains with variant 2 or 3. In the present study, we constructed a mutant of group B strain NZ98\/254 with attenuated endotoxin that expressed both endogenous variant 1 and heterologous fHbp variant 2. A mixture of the two native OMV vaccines from the H44\/76 and NZ98\/254 mutants stimulated proinflammatory cytokine responses by human peripheral blood mononuclear cells similar to those stimulated by control, detergent-treated OMV vaccines from the wild-type strains. In mice, the mixture of the two native OMV vaccines elicited broad serum bactericidal antibody responses against strains with heterologous PorA and fHbp in the variant 1, 2, or 3 group. By adsorption studies, the principal bactericidal antibody target was determined to be fHbp. Thus, native OMV vaccines from mutants expressing fHbp variants have the potential to be safe for humans and to confer broad protection against meningococcal disease from strains expressing fHbp from each of the antigenic variant groups.\n                  <\/jats:p>","DOI":"10.1128\/cvi.00403-08","type":"journal-article","created":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T20:54:27Z","timestamp":1230152067000},"page":"156-162","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2"],"prefix":"10.1128","volume":"16","author":[{"given":"Oliver","family":"Koeberling","sequence":"first","affiliation":[{"name":"Novartis Vaccines, Siena, Italy"},{"name":"Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California 94609"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Giuntini","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Siena, Italy"},{"name":"Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California 94609"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seubert","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Siena, Italy"},{"name":"Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California 94609"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Siena, Italy"},{"name":"Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California 94609"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00033-08"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00367-08"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1086\/514821","volume":"195","year":"2007","unstructured":"Beernink, P. T., J. A. Welsch, L. H. Harrison, A. Leipus, S. L. Kaplan, and D. M. Granoff. 2007. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis.195:1472-1479.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1574-6976.2006.00056.x","volume":"31","year":"2007","unstructured":"Brehony, C., K. A. Jolley, and M. C. Maiden. 2007. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol. Rev.31:15-26.","journal-title":"FEMS Microbiol. Rev."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.4049\/jimmunol.179.5.3222","volume":"179","year":"2007","unstructured":"Burke, J. M., L. M. Ganley-Leal, A. Khatri, and L. M. Wetzler. 2007. Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: potential adjuvant for helminth vaccines? J. Immunol.179:3222-3230.","journal-title":"J. Immunol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","volume":"17","year":"1999","unstructured":"Cartwright, K., R. Morris, H. Rumke, A. Fox, R. Borrow, N. Begg, P. Richmond, and J. Poolman. 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine17:2612-2619.","journal-title":"Vaccine"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1016\/j.vaccine.2005.06.011","volume":"23","year":"2005","unstructured":"Cox, A. D., W. Zou, M. A. Gidney, S. Lacelle, J. S. Plested, K. Makepeace, J. C. Wright, P. A. Coull, E. R. Moxon, and J. C. Richards. 2005. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine23:5045-5054.","journal-title":"Vaccine"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","volume":"18","year":"2000","unstructured":"de Kleijn, E. D., R. de Groot, J. Labadie, A. B. Lafeber, G. van den Dobbelsteen, L. van Alphen, H. van Dijken, B. Kuipers, G. W. van Omme, M. Wala, R. Juttmann, and H. C. Rumke. 2000. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine18:1456-1466.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1086\/320993","volume":"184","year":"2001","unstructured":"de Kleijn, E. D., R. de Groot, A. B. Lafeber, J. Labadie, C. J. van Limpt, J. Visser, G. A. Berbers, L. van Alphen, and H. C. Rumke. 2001. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J. Infect. Dis.184:98-102.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_11_2","first-page":"355","year":"1983","unstructured":"Finne, J., M. Leinonen, and P. H. Makela. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancetii:355-357.","journal-title":"Lancet"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_2_13_2","first-page":"81","year":"2001","unstructured":"Frasch, C., L. Van Alphen, J. Holst, J. Poolman, and E. Rosenqvist. 2001. Outer membrane protein vesicle vaccines for meningococcal disease, p. 81-107. In A. J. Pollard and M. C. Maiden (ed.), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, NJ.","journal-title":"Meningococcal vaccines: methods and protocols."},{"key":"e_1_3_2_14_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, et al. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-80.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","volume":"103","year":"2006","unstructured":"Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Arico, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, and M. Pizza. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA103:10834-10839.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01191-08"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/infdis\/171.6.1481","volume":"171","year":"1995","unstructured":"Hayrinen, J., H. Jennings, H. V. Raff, G. Rougon, N. Hanai, R. Gerardy-Schahn, and J. Finne. 1995. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis.171:1481-1490.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","volume":"3","year":"2007","unstructured":"Holst, J. 2007. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccines3:290-294.","journal-title":"Hum. Vaccines"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","volume":"23","year":"2005","unstructured":"Holst, J., B. Feiring, L. M. Naess, G. Norheim, P. Kristiansen, E. A. Hoiby, K. Bryn, P. Oster, P. Costantino, M. K. Taha, J. M. Alonso, D. A. Caugant, E. Wedege, I. S. Aaberge, R. Rappuoli, and E. Rosenqvist. 2005. The concept of \u201ctailor-made,\u201d protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23:2202-2205.","journal-title":"Vaccine"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/432102","volume":"192","year":"2005","unstructured":"Hou, V. C., O. Koeberling, J. A. Welsch, and D. M. Granoff. 2005. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J. Infect. Dis.192:580-590.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.187.10.3421-3430.2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","volume":"359","year":"2002","unstructured":"Jodar, L., I. Feavers, D. Salisbury, and D. M. Granoff. 2002. Development of vaccines against meningococcal disease. Lancet359:1499-1508.","journal-title":"Lancet"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","volume":"166","year":"2007","unstructured":"Kelly, C., R. Arnold, Y. Galloway, and J. O'Hallahan. 2007. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol.166:817-823.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","volume":"198","year":"2008","unstructured":"Koeberling, O., A. Seubert, and D. M. Granoff. 2008. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J. Infect. Dis.198:262-270.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.vaccine.2006.03.092","volume":"25","year":"2007","unstructured":"Koeberling, O., J. A. Welsch, and D. M. Granoff. 2007. Improved immunogenicity of a H44\/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine25:1912-1920.","journal-title":"Vaccine"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/424464","volume":"190","year":"2004","unstructured":"Litt, D. J., S. Savino, A. Beddek, M. Comanducci, C. Sandiford, J. Stevens, M. Levin, C. Ison, M. Pizza, R. Rappuoli, and J. S. Kroll. 2004. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis.190:1488-1497.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","volume":"177","year":"2006","unstructured":"Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177:501-510.","journal-title":"J. Immunol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","volume":"197","year":"2003","unstructured":"Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A. Welsch, D. M. Granoff, R. Rappuoli, and M. Pizza. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197:789-799.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.4049\/jimmunol.176.4.2373","volume":"176","year":"2006","unstructured":"Massari, P., A. Visintin, J. Gunawardana, K. A. Halmen, C. A. King, D. T. Golenbock, and L. M. Wetzler. 2006. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J. Immunol.176:2373-2380.","journal-title":"J. Immunol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.11.6021-6031.2002"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0378-1119(99)00557-0","volume":"244","year":"2000","unstructured":"Pagotto, F. J., H. Salimnia, P. A. Totten, and J. R. Dillon. 2000. Stable shuttle vectors for Neisseria gonorrhoeae,Haemophilus spp. and other bacteria based on a single origin of replication. Gene244:13-19.","journal-title":"Gene"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.3203-3213.2001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1086\/315833","volume":"182","year":"2000","unstructured":"Sacchi, C. T., A. M. Whitney, T. Popovic, D. S. Beall, M. W. Reeves, B. D. Plikaytis, N. E. Rosenstein, B. A. Perkins, M. L. Tondella, and L. W. Mayer. 2000. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J. Infect. Dis.182:1169-1176.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","volume":"176","year":"2006","unstructured":"Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol.176:7566-7575.","journal-title":"J. Immunol."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.174.6.3545","volume":"174","year":"2005","unstructured":"Singleton, T. E., P. Massari, and L. M. Wetzler. 2005. Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent. J. Immunol.174:3545-3550.","journal-title":"J. Immunol."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00005-08"},{"key":"e_1_3_2_37_2","first-page":"113","volume":"10","year":"2004","unstructured":"Steeghs, L., J. Tommassen, J. H. Leusen, J. G. van de Winkel, and P. van der Ley. 2004. Teasing apart structural determinants of \u2018toxicity\u2019 and \u2018adjuvanticity\u2019: implications for meningococcal vaccine development. J. Endotoxin Res.10:113-119.","journal-title":"J. Endotoxin Res."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","volume":"25","year":"2007","unstructured":"Taha, M. K., M. L. Zarantonelli, J. M. Alonso, L. M. Naess, J. Holst, B. Feiring, and E. Rosenqvist. 2007. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine25:2537-2538.","journal-title":"Vaccine"},{"key":"e_1_3_2_39_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.10.5981-5990.2001"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","volume":"188","year":"2003","unstructured":"Welsch, J. A., G. R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D. M. Granoff. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis.188:1730-1740.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","volume":"197","year":"2008","unstructured":"Welsch, J. A., S. Ram, O. Koeberling, and D. M. Granoff. 2008. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis.197:1053-1061.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.172.9.5606","volume":"172","year":"2004","unstructured":"Welsch, J. A., R. Rossi, M. Comanducci, and D. M. Granoff. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol.172:5606-5615.","journal-title":"J. Immunol."},{"key":"e_1_3_2_44_2","first-page":"9","volume":"33","year":"1983","unstructured":"Westphal, O., K. Jann, and K. Himmelspach. 1983. Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Prog. Allergy33:9-39.","journal-title":"Prog. Allergy"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1749-6632.1994.tb44295.x","volume":"730","year":"1994","unstructured":"Wetzler, L. M. 1994. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann. N. Y. Acad. Sci.730:367-370.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00411-07"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.10.6838-6845.2005"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/IAI.65.3.1053-1060.1997","volume":"65","year":"1997","unstructured":"Zollinger, W. D., E. E. Moran, S. J. Devi, and C. E. Frasch. 1997. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun.65:1053-1060.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1016\/j.vaccine.2007.03.029","volume":"25","year":"2007","unstructured":"Zughaier, S., L. Steeghs, P. van der Ley, and D. S. Stephens. 2007. TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine25:4401-4409.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00403-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00403-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:54:49Z","timestamp":1627559689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00403-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1128\/CVI.00403-08"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00403-08","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"2008-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-12-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}